An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole

Autor: Alexis Sonet, Frédérique Jacobs, Michel Aoun, Alain Gadisseur, Dominik Selleslag
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Male
Antifungal Agents
Time Factors
Aspergillosis
Triazoles -- administration & dosage -- adverse effects
Prospective Studies
Young adult
Prospective cohort study
Aged
80 and over
Mortality rate
Pyrimidines -- administration & dosage -- adverse effects
General Medicine
Middle Aged
Infectious Diseases
Treatment Outcome
Medical Microbiology
Female
medicine.drug
Microbiology (medical)
Adult
medicine.medical_specialty
Adolescent
Drug-Related Side Effects and Adverse Reactions
Article
Young Adult
Internal medicine
medicine
Internal Medicine
Humans
Adverse effect
Biology
Survival analysis
Antifungal Agents -- administration & dosage -- adverse effects
Drug Toxicity -- epidemiology
Aged
Voriconazole
business.industry
Triazoles
medicine.disease
Survival Analysis
Surgery
Clinical trial
Cancérologie
Biomedicine
Pyrimidines
Aspergillosis -- drug therapy -- mortality
Human medicine
business
Zdroj: European Journal of Clinical Microbiology & Infectious Diseases
European journal of clinical microbiology & infectious diseases, 31 (6
European journal of clinical microbiology and infectious diseases
ISSN: 1435-4373
0934-9723
Popis: The purpose of this study was to evaluate efficacy and safety of voriconazole in patients with acute invasive aspergillosis (IA) in a real-life, clinical setting. This was a multicenter observational study in adult patients treated with voriconazole for invasive mycosis. The study evaluated clinical response, mortality, use of other licensed antifungal therapy (OLAT), and treatment duration. This sub-analysis evaluated treatment and outcome data specifically from adult patients with proven/probable IA, while safety data were assessed in patients with proven/probable/possible IA. Of the 141 patients enrolled, 113 were adults with proven/probable IA and six had possible IA. Voriconazole treatment duration ranged from 1 to 183 days (median, 49.5 days). Voriconazole was used exclusively in 64% (72/113) of patients and in combination/sequentially with OLAT in 36%. Overall successful treatment response was 50% (57/113 patients). Twelve percent (14/113) of patients were switched to OLAT, either because of insufficient response (four patients) or for safety reasons (10 patients). Overall and attributable (entirely or partially due to fungal infection) mortality rates were 52% (59/113) and 17%, respectively. Treatment-related adverse events were reported for 18% (22/119) of patients. This observational study confirms the results of previous clinical trials demonstrating voriconazole as an effective and safe agent for treatment of confirmed acute IA.
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: